Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

Biogen Inc (NASDAQ: BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%.

Read Why Biogen Sares Are Trading Higher After Q1 Earnings

Biogen Inc  (NASDAQ:BIIB) stepped into the earnings confessional today to post first-quarter earnings of $3.62 per share -- lower than the $4.38 per share analysts anticipated -- due to Alzheimer's drug Adulhem inventory write-offs, and dismal sales of multiple sclerosis drug Tecfidera.

Biogen CEO Steps Down After Quarterly Earnings Miss

The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.

Biogen CEO Stepping Down After Struggles With Alzheimer's Drug Aduhelm

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q1 Earnings Miss Estimates

Biogen Inc. BIIB, -0.06% said Tuesday that it is conducting a search to replace CEO Michel Vounatsos, who will stay in his role unless a successor is named. The announcement was made in the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations for earnings and revenue.

Biogen CEO Michel Vounatsos to step down

Shares of Biogen Inc. BIIB, -0.06% fell 2.3% in premarket trading on Tuesday after the company missed Wall Street's expectations for revenue and earnings for the first quarter of 2022. Biogen had net income of $303.8 million, or $2.06 per share, in the first quarter of the year, down from $410.20, or $2.69 per share, in the first quarter of last year.

Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug

The biopharmaceutical company says it has begun to eliminate commercial infrastructure for Aduhelm, its Alzheimer's medication.

Biogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO

Biogen Inc said on Tuesday its Chief Executive Officer Michel Vounatsos will step down and the company has started a search for a successor.

Biogen CEO to step down

Esperion Therapeutics

Incyte

Pfizer

Teva Pharmaceutical

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics expands collaboration with Biogen to second target

Scribe Therapeutics Expands Collaboration With Biogen to Second Target

Sage Therapeutics Inc. SAGE, -2.78% and Biogen Inc. BIIB, -1.41% said Monday that they started a rolling submission to the Food and Drug Administration for zuranolone, a treatment they are developing for major depressive disorder. The full application, including clinical data, is set to be submitted in the second half of this year.

Sage, Biogen start 'rolling submission' to FDA for depression drug

SAGE Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug being developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module of the NDA to the FDA and plan to submit th

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Moderna

Novo Nordisk

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

On April 7, 2022, Medicare declined coverage of amyloid-based therapies without proven clinical benefit. This exceptional decision is a setback for Biogen, but investors were expecting it.

Biogen: Medicare Setback May Trigger Innovation And Partnerships

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.

Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Amgen

Corcept Therapeutics

Harmony Biosciences Holdings

Bio-Techne

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

7 Best Biotech Stocks to Build Your Portfolio

The company just withdrew its Aduhelm regulatory submission in the EU.

Things Just Got Worse for Biogen

The past year has been a bit stressful for this company and its shareholders.

Is This Biotech Stock Worth the Trouble?

Biogen Inc (NASDAQ: BIIB) has decided to withdraw the European marketing authorization application for its troubled Alzheimer's drug, aducanumab, after failing to convince the regulator of its benefits. The drugmaker said the move follows its interactions with the EMA's.

Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator

Biogen Inc. shares BIIB, -2.71% fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial Alzheimer's treatment aducanumab with the European regulator because early communications suggest the data is not sufficient to gain a positive opinion. "We stand by the safety and efficacy of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound," Priya Singhal, head of global safety & regulatory sciences and interim head of R&D at Biogen said in a statement.

Biogen stock slides 2% after it withdraws authorization application with EU regulator

Biogen's recent collapse isn't the end of the road by a long shot.

Down 16% Since October, Could This Stock Make a Turnaround?

Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer's drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal's bull case for the Biogen stock The Wells Fargo analyst upgraded BIIB on Monday to “overweight” and said the recent pullback makes the stock even […] The post Biogen needs ‘this' to unlock a 60% upside in its stock appeared first on Invezz.

Biogen needs ‘this' to unlock a 60% upside in its stock

Amylyx Pharmaceuticals

bluebird bio

Bristol-Myers

Gilead Sciences

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

News for Biogen Stock (BIIB)